1. Home
  2. RVPH vs ALTS Comparison

RVPH vs ALTS Comparison

Compare RVPH & ALTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVPH
  • ALTS
  • Stock Information
  • Founded
  • RVPH 2006
  • ALTS 1976
  • Country
  • RVPH United States
  • ALTS United States
  • Employees
  • RVPH N/A
  • ALTS N/A
  • Industry
  • RVPH Biotechnology: Pharmaceutical Preparations
  • ALTS
  • Sector
  • RVPH Health Care
  • ALTS
  • Exchange
  • RVPH Nasdaq
  • ALTS NYSE
  • Market Cap
  • RVPH 32.8M
  • ALTS 159.4M
  • IPO Year
  • RVPH N/A
  • ALTS N/A
  • Fundamental
  • Price
  • RVPH $0.37
  • ALTS $7.85
  • Analyst Decision
  • RVPH Strong Buy
  • ALTS
  • Analyst Count
  • RVPH 5
  • ALTS 0
  • Target Price
  • RVPH $9.00
  • ALTS N/A
  • AVG Volume (30 Days)
  • RVPH 2.6M
  • ALTS 298.8K
  • Earning Date
  • RVPH 08-13-2025
  • ALTS 08-18-2025
  • Dividend Yield
  • RVPH N/A
  • ALTS N/A
  • EPS Growth
  • RVPH N/A
  • ALTS N/A
  • EPS
  • RVPH N/A
  • ALTS N/A
  • Revenue
  • RVPH N/A
  • ALTS $18,046,000.00
  • Revenue This Year
  • RVPH N/A
  • ALTS $185.91
  • Revenue Next Year
  • RVPH N/A
  • ALTS $64.93
  • P/E Ratio
  • RVPH N/A
  • ALTS N/A
  • Revenue Growth
  • RVPH N/A
  • ALTS N/A
  • 52 Week Low
  • RVPH $0.30
  • ALTS $1.29
  • 52 Week High
  • RVPH $4.28
  • ALTS $10.95
  • Technical
  • Relative Strength Index (RSI)
  • RVPH 30.28
  • ALTS 47.87
  • Support Level
  • RVPH $0.35
  • ALTS $6.62
  • Resistance Level
  • RVPH $0.83
  • ALTS $10.38
  • Average True Range (ATR)
  • RVPH 0.07
  • ALTS 1.04
  • MACD
  • RVPH -0.04
  • ALTS -0.29
  • Stochastic Oscillator
  • RVPH 11.32
  • ALTS 38.52

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

About ALTS ALT5 SIGMA CORPORATION

ALT5 Sigma Corp is a fintech company. The company operates in three operating segments: Fintech: provides next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, Biotechnology: Biotechnology segment is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties; Corporate and Others: Corporate and Other segment consists of certain corporate general and administrative costs. Company has revenue from Fintech Segment.

Share on Social Networks: